David J. Gladstone

David J. Gladstone

Auto-generated profile, based on publicly available information

David J. Gladstone

Department of Neurology, University of Toronto, Ontario, Canada (D.J.G.).

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Neurorehabilitation and Neural Repair
Verified
Journal Article
Open access
PDF file
DGDavid J. Gladstone
David J. Gladstone
CDCynthia J. Danells
Cynthia J. Danells
SBSandra E. Black
Sandra E. Black
Measurement of recovery after stroke is becoming increasingly important with the advent of new treatment options under investigation in stroke rehabilitation research. The Fugl-Meyer scale was developed as the first quantitative evaluative instrument for measuring sensorimotor stroke recovery, based on Twitchell and Brunnstrom’s concept of sequential stages of motor return in the hemiplegic stroke patient. The Fugl-Meyer is a well-designed, feasible and efficient clinical examination method that has been tested widely in the stroke population. Its primary value is the 100-point motor domain, which has received the most extensive evaluation. Excellent interrater and intrarater reliability and construct validity have been demonstrated, and preliminary evidence suggests that the Fugl-Meyer assessment is responsive to change. Limitations of the motor domain include a ceiling effect, omission of some potentially relevant items, and weighting of the arm more than the leg. Further study should test performance of this scale in specific subgroups of stroke patients and better define its criterion validity, sensitivity to change, and minimal clinically important difference. Based on the available evidence, the Fugl-Meyer motor scale is recommended highly as a clinical and research tool for evaluating changes in motor impairment following stroke.

26 June 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
DGDavid J. Gladstone
David J. Gladstone
MSMelanie Spring
Melanie Spring
PDPaul Dorian
Paul Dorian
VPVal Panzov
Val Panzov
KTKevin E. Thorpe
Kevin E. Thorpe
MMMuhammad Mamdani
Muhammad Mamdani
Atrial fibrillation is a leading preventable cause of recurrent stroke for which early detection and treatment are critical. However, paroxysmal atrial fibrillation is often asymptomatic and likely to go undetected and untreated in the routine care of patients with ischemic stroke or transient ischemic attack (TIA). We randomly assigned 572 patients 55 years of age or older, without known atrial fibrillation, who had had a cryptogenic ischemic stroke or TIA within the previous 6 months (cause undetermined after standard tests, including 24-hour electrocardiography [ECG]), to undergo additional noninvasive ambulatory ECG monitoring with either a 30-day event-triggered recorder (intervention group) or a conventional 24-hour monitor (control group). The primary outcome was newly detected atrial fibrillation lasting 30 seconds or longer within 90 days after randomization. Secondary outcomes included episodes of atrial fibrillation lasting 2.5 minutes or longer and anticoagulation status at 90 days. Atrial fibrillation lasting 30 seconds or longer was detected in 45 of 280 patients (16.1%) in the intervention group, as compared with 9 of 277 (3.2%) in the control group (absolute difference, 12.9 percentage points; 95% confidence interval [CI], 8.0 to 17.6; P<0.001; number needed to screen, 8). Atrial fibrillation lasting 2.5 minutes or longer was present in 28 of 284 patients (9.9%) in the intervention group, as compared with 7 of 277 (2.5%) in the control group (absolute difference, 7.4 percentage points; 95% CI, 3.4 to 11.3; P<0.001). By 90 days, oral anticoagulant therapy had been prescribed for more patients in the intervention group than in the control group (52 of 280 patients [18.6%] vs. 31 of 279 [11.1%]; absolute difference, 7.5 percentage points; 95% CI, 1.6 to 13.3; P=0.01). Among patients with a recent cryptogenic stroke or TIA who were 55 years of age or older, paroxysmal atrial fibrillation was common. Noninvasive ambulatory ECG monitoring for a target of 30 days significantly improved the detection of atrial fibrillation by a factor of more than five and nearly doubled the rate of anticoagulant treatment, as compared with the standard practice of short-duration ECG monitoring. (Funded by the Canadian Stroke Network and others; EMBRACE ClinicalTrials.gov number, NCT00846924.)

15 January 2009 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ITI.Y.L. Tan
I.Y.L. Tan
ADA.M. Demchuk
A.M. Demchuk
JHJ. Hopyan
J. Hopyan
LZL. Zhang
L. Zhang
DGD. Gladstone
D. Gladstone
RAR.I. Aviv
R.I. Aviv
BACKGROUND AND PURPOSE: Clot extent, location, and collateral integrity are important determinants of outcome in acute stroke. We hypothesized that a novel clot burden score (CBS) and collateral score (CS) are important determinants of clinical and radiologic outcomes and serve as useful additional stroke outcome predictors.

1 April 2007 in Stroke
Verified
Journal Article
Open access
PDF file
RWRyan Wada
Ryan Wada
RARichard I. Aviv
Richard I. Aviv
AFAllan J. Fox
Allan J. Fox
DSDemetrios J. Sahlas
Demetrios J. Sahlas
DGDavid J. Gladstone
David J. Gladstone
SSSean P. Symons
Sean P. Symons
Background and Purpose— Morbidity and mortality in spontaneous intracerebral hemorrhage (ICH) are correlated with hematoma progression. We hypothesized that the presence of tiny, enhancing foci (“spot sign”) within acute hematomas is associated with hematoma expansion. Methods— We prospectively studied 39 consecutive patients with spontaneous ICH by computed tomography angiography within 3 hours of symptom onset. Scans were reviewed by 3 readers. Patients were dichotomized according to the presence or absence of the spot sign. Clinical and radiological outcomes were compared between groups. The predictive value of this sign was assessed in a multivariate analysis. Results— Thirteen patients (33%) demonstrated 31 enhancing foci. Baseline clinical variables were similar in both groups. Hematoma expansion occurred in 11 patients (28%) on follow-up. Seventy-seven percent of patients with and 4% without hematoma expansion demonstrated the spot sign ( P <0.0001). Sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio for expansion were 91%, 89%, 77%, 96%, and 8.5, respectively. Interobserver agreement was high (κ=0.92 to 0.94). In patients with the spot sign, mean volume change was greater ( P =0.008), extravasation more common ( P =0.0005), and median hospital stay longer ( P =0.04), and fewer patients achieved a good outcome (modified Rankin Scale score <2), although the latter was not significant ( P =0.16). No differences in hydrocephalus ( P =1.00), surgical intervention ( P =1.00), or death ( P =0.60) were noted between groups. In multiple regression, the spot sign independently predicted hematoma expansion ( P =0.0003). Conclusions— The computed tomography angiography spot sign is associated with the presence and extent of hematoma progression. Fewer patients achieve a good clinical outcome and hospital stay was longer. Further studies are warranted to validate the ability of this sign to predict clinical outcomes.

1 April 2012 in The Lancet Neurology
Verified
Journal Article
Closed access
ADAndrew M Demchuk
Andrew M Demchuk
DDDar Dowlatshahi
Dar Dowlatshahi
DRDavid Rodriguez-Luna
David Rodriguez-Luna
CMCarlos A Molina
Carlos A Molina
YBYolanda Silva Blas
Yolanda Silva Blas
RARichard I Aviv
Richard I Aviv

1 August 2002 in Stroke
Verified
Journal Article
Closed access
PDF file
DGDavid J. Gladstone
David J. Gladstone
SBSandra E. Black
Sandra E. Black
AHAntoine M. Hakim
Antoine M. Hakim
Background — Neuroprotective drugs for acute stroke have appeared to work in animals, only to fail when tested in humans. With the failure of so many clinical trials, the future of neuroprotective drug development is in jeopardy. Current hypotheses and methodologies must continue to be reevaluated, and new strategies need to be explored. Summary of Review — In part 1, we review key challenges and complexities in translational stroke research by focusing on the “disconnect” in the way that neuroprotective agents have traditionally been assessed in clinical trials compared with animal models. In preclinical studies, determination of neuroprotection has relied heavily on assessment of infarct volume measurements (instead of functional outcomes), short-term (instead of long-term) end points, transient (instead of permanent) ischemia models, short (instead of extended) time windows for drug administration, and protection of cerebral gray matter (instead of both gray and white matter). Clinical trials have often been limited by inappropriately long time windows, insufficient statistical power, insensitive outcome measures, inclusion of protocol violators, failure to target specific stroke subtypes, and failure to target the ischemic penumbra. In part 2, we explore new concepts in ischemic pathophysiology that should encourage us also to think beyond the hyperacute phase of ischemia and consider the design of trials that use multiagent therapy and exploit the capacity of the brain for neuroplasticity and repair. Conclusions — By recognizing the strengths and limitations of animal models of stroke and the shortcomings of previous clinical trials, we hope to move translational research forward for the development of new therapies for the acute and subacute stages after stroke.